GENESIS-PHARMA
GENESIS Pharma, a regional biopharma company specialized in the commercialization of innovative medicines targeting severe and rare diseases in Central and Eastern Europe, announces an exclusive distribution agreement for the cancer medicine cemiplimab in Greece, Cyprus and Malta with Regeneron Ireland DAC. Regeneron Ireland DAC is a wholly owned subsidiary of Regeneron, a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases.
Cemiplimab is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells and was invented using Regeneron's proprietary VelocImmune® technology. In the European Union, cemiplimab is indicated for adults as monotherapy treatment for certain patients with locally advanced or metastatic basal cell carcinoma (BCC), as monotherapy treatment for certain patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC), as both monotherapy or in combination with chemotherapy for certain patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and as monotherapy treatment for certain patients with recurrent or metastatic cervical cancer.
The two companies will work to seamlessly complete the transition of all relevant commercialization activities by the second quarter of 2024.
Mr. Constantinos Evripides, Managing Director of GENESIS Pharma stated: “For more than 20 years our company has been committed to ensure patient access to innovative therapies for serious diseases in several European markets building upon a constantly growing network of partners that includes leading global biopharma companies. It is thus our honor to initiate a new agreement with Regeneron, a pioneering company committed to cutting-edge science, that further enhances our long-term expertise and focus on medicines targeting difficult-to-treat cancers.”
About GENESIS Pharma: GENESIS Pharma is a regional biopharma company focused on the commercialization of innovative biopharmaceutical products targeting severe and rare diseases in Central and Eastern Europe. Established in 1997, GENESIS Pharma was among the first pharmaceutical companies in Europe to specialize in the marketing, sales and distribution of biopharmaceutical products. GENESIS Pharma maintains a strong portfolio in therapeutic areas with high unmet medical need through long standing strategic alliances with some of the leading global biopharma companies.
For more information, please visit www.genesispharmagroup.com or follow GENESIS Pharma on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240301136761/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors22.10.2025 02:25:00 CEST | Press release
Takeda to Receive Rights to Two Next-Generation Late-Stage Investigational Medicines, Worldwide Outside of Greater China, and an Exclusive Option to License Global Rights to an Early-Stage ProgramTakeda to Lead IBI363 Global Co-Development and U.S. Co-Commercialization and Will Have Exclusive Commercialization Rights Outside the U.S. and Greater China; IBI363 is a Late-Stage Bispecific Antibody Fusion Protein Being Evaluated in Non-Small Cell Lung and Colorectal Cancers, with Potential in Additional Solid Tumor TypesTakeda to Receive Exclusive Rights for IBI343 Outside of Greater China; IBI343 is a Late-Stage Antibody-Drug Conjugate Being Evaluated in Gastric and Pancreatic CancersTakeda Intends to Establish Manufacturing for These Investigational Medicines in the U.S. Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into a license and collaboration agreement with Innovent Biologics (HKEX: 01801) for the development, manufacturing and commercialization of two late-stage o
YES Selected to Deliver Full Portfolio of Advanced Packaging Tools for Glass Panel AI and HPC Applications by a Leading AI Infrastructure Supplier21.10.2025 21:16:00 CEST | Press release
Yield Engineering Systems (YES), a leading provider of advanced process equipment for AI and high-performance computing (HPC) semiconductor applications, today announced that it has received multiple tool orders from a global leader in AI infrastructure solutions. The orders span YES’s portfolio of Dry and Wet process systems and will support panel-level manufacturing on glass substrates for next-generation data center and HPC packaging. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020459437/en/ YES VertaCure, VertaPrime, VeroFlex, TersOra, and SURE systems. The systems will be deployed in advanced packaging lines dedicated to hyperscale AI workloads, including training, inference, networking, and co-packaged optics. This award marks a significant milestone in the industry's shift toward glass-based 2.5D and 3D packaging as system performance, density, and thermal requirements escalate. YES will supply a full suite of s
Esri and UNFPA Extend Strategic Partnership to Support 2030 Census Round21.10.2025 21:09:00 CEST | Press release
Collaboration Strengthens Census Through Location-Enabled Data Sharing Esri, the global leader in location intelligence, today announced the extension of its strategic partnership with the United Nations Population Fund (UNFPA) in support of the 2030 census round. Building on a successful collaboration during the 2020 census round, the partnership aims to embed geographic information system (GIS) technology into all phases of census work. By leveraging GIS, national statistics and census offices will gain access to more authoritative, location-enabled data and faster, more efficient methods of planning, collection, and dissemination. “National census projects can often involve mapping an entire country,” said Linda Peters, Esri global business development manager. “GIS is becoming crucial for every step of a census but deploying it is new to many national statistical offices. We are happy to provide the resources that can enable this large-scale feat of authoritative data collection an
AXS and Lawson Entertainment Partner to Enhance Fan Ticketing Experiences in Japan21.10.2025 20:41:00 CEST | Press release
AXS, the trusted leader in advanced ticketing and live event technology, today announced the establishment of AXS Tickets, a new joint venture with Lawson Entertainment, one of Japan’s leading entertainment and ticketing companies, marking a major expansion of AXS’s business in Japan. This partnership builds on AXS’s successful presence in Japan, combining AXS’s world-class technology and global expertise with Lawson Entertainment’s (Lawson Tickets’) deep industry relationships and highly recognized consumer brand. Together, they aim to expand access to live entertainment and sports across Japan. Since its launch in 2018, AXS Japan has powered ticketing for thousands of events and sold tens of millions of tickets for some of the country’s fastest-growing sports leagues, professional teams, and major event organizers. The creation of AXS Tickets strengthens that foundation — enabling AXS and Lawson Entertainment to deliver a new level of innovation and scale for artists, promoters, venu
ChipAgents Raises Oversubscribed $21M Series A to Redefine AI for Chip Design21.10.2025 16:30:00 CEST | Press release
Sales 50x YoY, Deployments at 50 leading semiconductor companies. Former CEOs of Cadence and Mentor Graphics, Plus Former Synopsys CTO, Join Advisory Board. Today ChipAgents, the agentic AI platform transforming chip design and verification, announced the close of a $21 million Series A funding round, bringing the total fundraise to $24 million to date. This latest round closed with Bessemer Venture Partners, with strategic backing from Micron, MediaTek, Ericsson, and additional top semiconductor companies. Also participating in the round are notable angels including new advisors, Wally Rhines, Raúl Camposano,and Jack Harding, and existing support by ScOp Venture Capital (Ivan Bercovich) and Amino Capital, fueling the company’s expansion of product development, customer acquisition, and strategic industry partnerships. ChipAgents’ mission is to bring the power of AI to the heart of chip design and verification. Every engineer should be empowered with tools that make the most complex as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom